TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00950599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 2.5 mg, once daily, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 5 mg, once daily, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 10 mg, once daily, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 20 mg, once daily, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 40 mg, once daily, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 100 mg, once daily, 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, once daily, 6 and 12 weeks
Study: NCT00459381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib hydrochloride
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00764049

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single pass albumin dialysis
Description: 6 hours sessions of albumin dialysis.
Study: NCT03104088

Intervention type: DIAGNOSTIC_TEST
Intervention: CANTAB
Description: CANTAB Cognitive Assessment (tablet based cognitive testing from CAMCOG)

Intervention type: DIAGNOSTIC_TEST
Intervention: CANTAB
Description: CANTAB Cognitive Assessment (tablet based cognitive testing from CAMCOG)

Intervention type: DIAGNOSTIC_TEST
Intervention: MOCA
Description: Montreal cognitive assessment (MOCA) in German

Intervention type: DIAGNOSTIC_TEST
Intervention: MOCA
Description: Montreal cognitive assessment (MOCA) in German
Study: NCT02934386

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WinMedical WinPack device
Study: NCT04036227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-248
Description: GS-248 oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral solution with the same composition to match active drug
Study: NCT02569840

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Amino Acid Feed
Description: Each child will receive the amino acid based feed for a period of up to 4 weeks (28 days). The feed prescription will be determined on an individual basis by the Dietitian responsible for the child's nutritional management. The child will take the feed orally or via a pre-existing naso-gastric, gastrostomy or jejunostomy tube.
Study: NCT01247896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457
Description: Single Dose 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457
Description: Single Dose 10 mg
Study: NCT00906672

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flap technique
Description: A flap is a part of skin, cutaneous tissue or muscle that is taken from an healthy area of the body and put on the damaged area for coverage.
Study: NCT04144673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Silver Hydrosol
Description: Silver quantity will be 7 doses per day, with 50 mcg per dose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo water with no active ingredients
Study: NCT00982462

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) and arachidonic acid (ARA)
Description: Micro-encapsulated powder containing the long-chain polyunsaturated fatty acids, DHA to ARA in a 1:1 ratio. Two foil-packets containing active intervention (200mg DHA+200mg ARA) or placebo (400 mg corn oil) per day added to a selection of recommended foods.
Study: NCT01247896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457
Description: Single Dose 30 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457
Description: Single Dose 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457
Description: Single Dose 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457
Description: Single Dose 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457
Description: Single Dose - to be determined with food
Study: NCT00982462

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn oil placebo
Description: Micro-encapsulated powder containing corn oil as the placebo.
Study: NCT04396067

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aerosolized 13 cis retinoic acid
Description: The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aerosolized All trans retinoic acid
Description: The infected patients will receive Aerosolized All trans retinoic acid in gradual one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled all trans retinoic acid therapy for 14 days
Study: NCT01247896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457
Description: Single Dose - to be determined

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single Dose Placebo
Study: NCT00271999

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nocturnal home hemodialysis
Description: Six times per week nocturnal home hemodialysis

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nocturnal home hemodialysis
Description: Six times per week nocturnal home hemodialysis
Study: NCT01521767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolterodine tartrate
Description: 4 mg single dose of extended release capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolterodine tartrate
Description: 4 mg single dose of microspheres in powder blend
Study: NCT04396067

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a pill or tablet that does not contain any study drug.
Study: NCT01521767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolterodine tartrate
Description: 4 mg single dose of microspheres in powder blend

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolterodine tartrate
Description: 4 mg single dose of microspheres in powder blend

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolterodine tartrate
Description: 4 mg single dose of microspheres in powder blend
Study: NCT04681222

Intervention type: PROCEDURE
Intervention: LFCN
Description: LFCN block was performed in combination with PENG block

Intervention type: PROCEDURE
Intervention: Wound infiltration
Description: Wound infiltration was performed in combination with PENG block
Study: NCT02483481

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: shear wave ultrasound elastography
Description: shear wave ultrasound elastography
Study: NCT03931057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADV6209 (=gamma-cyclodextrin-Midazolam)
Description: 30 min. before anesthesia children have to swallow the anxiolytic drug (ADV6209)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 30 min. before anesthesia children have to swallow the anxiolytic drug Midazolam
Study: NCT00807625

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depo Provera
Description: Depo Provera administered by injection at randomization visit and the 12-week study visit.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Copper T Intrauterine contraception device
Description: IUCD inserted upon randomization to this study arm
Study: NCT00028730

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT01406873

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mexiletine
Description: 150 mg/kg Mexiletine capsules taken by mouth, three times daily for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 150 mg/kg placebo capsules taken by mouth, three times daily for 6 months
Study: NCT02619331

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allergy test reading
Description: Reading of allergy skin tests (in response to allergen extracts or histamine or negative control) by HSL-DI versus direct observer evaluation (CWFM)
Study: NCT02077192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib Disodium
Description: Fostamatinib Disodium tablet 100 mg or 150 mg by mouth twice a day
Study: NCT03796299

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of expression of MCM5 in the urine (ADX Bladder)
Description: Each participant will be asked to urinate in a plastic container. Urine will be centrifuged afterwards, then the expression of MCM5 protein will be examined in cells from urine sediment. For this purpose, it is planned to use the Arquer Diagnostics ADXBLADDER test. It is an enzyme linked immunosorbent assay (ELISA) using two monoclonal antibodies directed against two different epitopes. Both antibodies have high affinity and specificity for the MCM5 antigen.

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of expression of MCM5 in the urine (ADX Bladder)
Description: Each participant will be asked to urinate in a plastic container. Urine will be centrifuged afterwards, then the expression of MCM5 protein will be examined in cells from urine sediment. For this purpose, it is planned to use the Arquer Diagnostics ADXBLADDER test. It is an enzyme linked immunosorbent assay (ELISA) using two monoclonal antibodies directed against two different epitopes. Both antibodies have high affinity and specificity for the MCM5 antigen.

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of expression of MCM5 in the urine (ADX Bladder)
Description: Each participant will be asked to urinate in a plastic container. Urine will be centrifuged afterwards, then the expression of MCM5 protein will be examined in cells from urine sediment. For this purpose, it is planned to use the Arquer Diagnostics ADXBLADDER test. It is an enzyme linked immunosorbent assay (ELISA) using two monoclonal antibodies directed against two different epitopes. Both antibodies have high affinity and specificity for the MCM5 antigen.
Study: NCT01315483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight Loss Dietary Pattern
Description: Diet-physical activity program creating a weekly negative energy balance equivalent to 3500 kcal. Intervention groups receive PA protocol promoting the Physical Activity Guidelines and translated in step recommendations, but one of two diets with divergent dietary patterns (opposing fat and CHO content) that do not overlap \>+5% in CHO and fat content. Macronutrient values reflect a 'pattern' or ratio within (LC 3:2 ratio for F:CHO; HC 1:4 ratio for F:CHO ) and between diets (LC:HC 3:1 for fat; LC:HC 1:2 for CHO). Six-week meal plans for five calorie levels available and incorporate educational material, supporting program components (e.g. self monitoring tools) and core competencies reinforcing weight loss behaviors in order to promote high levels of dietary adherence.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight Loss Dietary Pattern
Description: Diet-physical activity program creating a weekly negative energy balance equivalent to 3500 kcal. Intervention groups receive PA protocol promoting the Physical Activity Guidelines and translated in step recommendations, but one of two diets with divergent dietary patterns (opposing fat and CHO content) that do not overlap \>+5% in CHO and fat content. Macronutrient values reflect a 'pattern' or ratio within (LC 3:2 ratio for F:CHO; HC 1:4 ratio for F:CHO ) and between diets (LC:HC 3:1 for fat; LC:HC 1:2 for CHO). Six-week meal plans for five calorie levels available and incorporate educational material, supporting program components (e.g. self monitoring tools) and core competencies reinforcing weight loss behaviors in order to promote high levels of dietary adherence.
Study: NCT01272193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Injected subcutaneously (under the skin) once daily prior to the largest meal of the day as monotherapy or combined with no more than 2 oral anti-diabetic drugs (OADs).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Administered according to approved labelling either as monotherapy or combined with no more than 2 OADs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Administered according to approved labelling either as monotherapy or combined with no more than 2 OADs.
Study: NCT01918709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 1 : Period 1(V) Period 2(R) Period 3(V+R)
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 1 : Period 1(V) Period 2(R) Period 3(V+R)
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 1 : Period 1(V) Period 2(R) Period 3(V+R)
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 2 : Period 1(V+R) Period 2(V) Period 3(R)
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 2 : Period 1(V+R) Period 2(V) Period 3(R)
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 2 : Period 1(V+R) Period 2(V) Period 3(R)
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 3 : Period 1(R) Period 2(V+R) Period 3(V)
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 3 : Period 1(R) Period 2(V+R) Period 3(V)
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 3 : Period 1(R) Period 2(V+R) Period 3(V)
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 4 : Period 1(V+R) Period 2(R) Period 3(V)
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 4 : Period 1(V+R) Period 2(R) Period 3(V)
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
Study: NCT04666272

Intervention type: DRUG
Intervention: dabrafenib
Description: There is no treatment allocation. Patients administered dabrafenib alone by prescription that have started before inclusion of the patient into the study could be enrolled.

Intervention type: DRUG
Intervention: trametinib
Description: There is no treatment allocation. Patients administered trametinib alone by prescription that have started before inclusion of the patient into the study could be enrolled.
Study: NCT04644354

Intervention type: DRUG
Intervention: Nifedipine 10 mg
Description: For both groups, when preterm labor is diagnosed, 10 mg capsule will be given sublinguially and if it is not effective in 1 hour, the same dose will be repeated again, and the same regimen will be repeated every day till preterm labor ends or proceed to a preterm birth.

Intervention type: DRUG
Intervention: Nifedipine 10 mg
Description: For both groups, when preterm labor is diagnosed, 10 mg capsule will be given sublinguially and if it is not effective in 1 hour, the same dose will be repeated again, and the same regimen will be repeated every day till preterm labor ends or proceed to a preterm birth.
Study: NCT03553459

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Trendelenburg Maneuver
Description: In the Trendelenburg position, the body is laid supine, or flat on the back with the feet higher than the head by 15-30 degrees. The venous return increases in the trendelenburg position which in turn increases the stroke volume.
Study: NCT01918709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 4 : Period 1(V+R) Period 2(R) Period 3(V)
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 5 : Period 1(R) Period 2(V) Period 3(V+R)
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 5 : Period 1(R) Period 2(V) Period 3(V+R)
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 5 : Period 1(R) Period 2(V) Period 3(V+R)
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 6 : Period 1(V) Period 2(V+R) Period 3(R)
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 6 : Period 1(V) Period 2(V+R) Period 3(R)
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 6 : Period 1(V) Period 2(V+R) Period 3(R)
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
Study: NCT00796289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH iontophoretic transdermal Lutrepatch
Description: 10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day (every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'high target' study dose, which is estimated to be 800 picograms/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH iontophoretic transdermal Lutrepatch
Description: 10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day(every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'medium target' study dose, which is estimated to be 400-600 picograms/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH iontophoretic transdermal Lutrepatch
Description: 10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day (every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'low target' study dose, which is estimated to be 200 picograms/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene citrate
Description: Oral, 50 mg daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo clomiphene citrate
Description: oral, taken for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo clomiphene citrate
Description: oral, taken for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo clomiphene citrate
Description: oral, taken for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo clomiphene citrate
Description: oral, taken for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo GnRH patch
Description: Placebo transdermal patch with a high target delivery of placebo(every 90 minutes). New patch to be applied every 12 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo GnRH patch
Description: Placebo transdermal patch with a high target delivery of placebo(every 90 minutes). New patch to be applied every 12 hours.
Study: NCT02118753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: eplerenone administered ex vivo (to the organ bath in which human atrial tissue is exposed)
Study: NCT02464878

Intervention type: DRUG
Group type: OTHER
Intervention: Alpha 1-Antitrypsin
Description: Patients will receive three times a week AAT infusions in the peri-transplant period for three weeks.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Islet Transplantation

Intervention type: DRUG
Group type: OTHER
Intervention: Thymoglobulin
Description: Patients will receive a total of 5 doses between Day -2 and Day +2

Intervention type: DRUG
Group type: OTHER
Intervention: Basiliximab
Description: Basiliximab will be used for subsequent transplants.

Intervention type: DRUG
Group type: OTHER
Intervention: Etanercept
Description: Etanercept will be given on the day of transplant and on Days 3, 7, and 10 post-transplant.
Study: NCT01682473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSTK474
Description: Two arms, each with serial cohorts receiving escalating doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSTK474
Description: Two arms, each with serial cohorts receiving escalating doses.
Study: NCT01805310

Intervention type: OTHER
Group type: OTHER
Intervention: Bowel preparation
Description: Subjects randomized to the mechanical bowel preparation arm will be instructed to consume 300cc of magnesium citrate no later than 3PM on preoperative day number one.

Intervention type: OTHER
Group type: OTHER
Intervention: No bowel preparation
Description: Subjects randomized to no bowel preparation will be instructed to continue a regular diet on preoperative day number one.
Study: NCT03634332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGPH20
Description: PEGPH20 is a PEGylated, neutral-pH-active human hyaluronidase PH20 produced by recombinant DNA technology

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2